Navigation Links
Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform
Date:7/22/2014

SOUTH EASTON, Mass., July 22, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") and Parabase Genomics ("Parabase"), (together "the companies"), today announced they have entered into a strategic research and development agreement (the "collaboration"). Under the terms of the collaboration, PBI will develop a front-end, sample preparation method for Parabase's enhanced neonatal molecular diagnostics and newborn confirmatory testing process. The sample preparation method will be based on PBI's patented and enabling Pressure Cycling Technology ("PCT") platform.

Each year around 4 million babies are born in the United States, with approximately 400,000 admitted to the Neonatal Intensive Care Unit ("NICU"). Roughly 150,000 newborns need at least one single-gene test, since many of the approximately 4,000 identified single-gene diseases present in the first month of life. Early diagnosis is critical so that treatment to prevent mortality or lifelong debilitation can be quickly initiated. Unfortunately, it is difficult to diagnose genetic disease in newborns based on symptoms alone as 80% of cases present with nonspecific or similar symptoms that can have upwards of 160 possible different diagnoses. Serially testing single genes in these cases, which is the current state-of-the-art, can take many months and be prohibitively expensive.

Dr. Andy Bhattacharjee, Chief Scientific Officer and Founder of Parabase Genomics, said: "Parabase uses targeted next generation sequencing ("NGS") to offer comprehensive test panels to diagnose single-gene conditions in newborns. Our goal is to improve the standard-of-care in NICUs by replacing hundreds of currently used single-gene-disorder tests with our LifeTime NewbornDx™ sequencing service to simultaneously evaluate 350 genes representing genetic disorders in the newborn period. We plan to do this in a minimally invasive fashion, such as processing dried blood spot specimens that are currently taken from every newborn. In this regard, we are pleased to collaborate with our colleagues at PBI, who have years of experience and expertise in successfully extracting biomolecules like DNA from various sample types with their patented PCT Platform."

Dr. Bhattacharjee continued: "Our process will be optimized for 48-hour results, compared to the 8-16 weeks typically needed to generate a clinical report. This vast improvement in time to diagnosis should lead to better therapeutic options and patient outcomes, and lower economic burden due to less exploratory testing and shorter hospital stays."

Dr. Alexander Lazarev, Vice President of Research and Development at PBI, commented: "Performing NGS testing on dried blood spot samples is novel and far from trivial. Based on our prior success with similar specimens, we believe the PCT Platform has certain intrinsic capabilities that will enable the extraction and recovery of sufficient amounts of high quality DNA from these specimens for subsequent testing with the LifeTime NewbornDx™ NGS service."

Dr. Lazarev continued: "We look forward to working with our Parabase Genomics colleagues in helping to develop this important sequencing service, for both its possible impact on improving the lives of children through early diagnosis of genetic diseases, and for its potential commercial success for both our companies."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.      

About Parabase Genomics
Parabase Genomics is a privately-held, commercial-stage biotechnology company that uses targeted next generation sequencing to offer comprehensive test panels and exomes to diagnose single-gene conditions in newborns. We currently offer the LifeTime NewbornDx™ and LifeTime RareDx™ gene sequencing services. These are CLIA laboratory-based services primarily serving neonatal intensive care units. Our tests employ end-to-end workflow as well as insurance pre-verification and billing services. We have developed a non-invasive sequencing method using dried blood spots, which is the first of its kind and allows us to process small sample sizes, archival samples, or work in remote locations. Our LifeTime Database™ of rare variants allows us to detect new mutations other tests would miss, thus providing a more accurate diagnosis.      

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:  
http://www.pressurebiosciences.com 
Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:


Richard T. Schumacher, President and CEO, PBI

(508) 230-1828 (T)

G. Hamilton Mehlman, CEO, Parabase Genomics

(617) 875-7822 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
5. Negative Pressure Wound Therapy (NPWT) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
6. Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
7. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
8. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
9. Long-Term Use of Blood Pressure Medications that Promote Sun Sensitivity May Increase Risk of Lip Cancer in Non-Hispanic Whites
10. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... Dec. 6, 2016  Viking Therapeutics, Inc. ("Viking") ... company focused on the development of novel therapies ... the U.S. Food and Drug Administration (FDA) has ... treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a ... that selectively regulates the expression of genes believed ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Blueprint Medicines ... discovering and developing targeted kinase medicines for patients with ... an underwritten public offering of $125,000,000 million in shares ... to grant the underwriters a 30-day option to purchase ... of its common stock in connection with the public ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo reveals ... of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. Easily ... from a variety of flip book animations. In Addition, users can modify each preset ...
(Date:12/7/2016)... ... December 07, 2016 , ... Bioelectronic ... Plus for consumers and healthcare professionals to manage chronic and acute pain. ... treatment modalities available in a single device. The announcement is part of ...
(Date:12/7/2016)... ... 2016 , ... “The Road To Restoration”: an informative and enlightening book ... a week showing of hands. “The Road To Restoration” is the creation of published ... with the brass ring that you could reach out for, and grab, on the ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons ... will inspire the reader to be aware of God's direction in their lives. “Walking ... Sanford Smith, retired teacher and active church leader. , Sanford says, “I ...
Breaking Medicine News(10 mins):